Identity
Vilon is the dipeptide Lys-Glu (KE), explicitly named in animal experiments and a Russian human report.
Catalog identity only; not authentication of a purchased vial or clinical approval.
Peptide library
Vilon
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Calling Vilon unidentified, or claiming only cell evidence exists, was too broad. Its sequence and a human report are documented, but biomarker findings cannot establish immune enhancement, longevity or a safe general regimen.
About this assessment
Identity sources and selected source evidence assessed; scope below.
Human report located; full Russian methods/results not obtained in this pass. Indexing as randomized does not establish low risk of bias. No treatment recommendation or clinician sign-off.
Editorial assessment · 2026-09-07
Who was studied
Patients with type 1 diabetes in a Russian report indexed as a randomized controlled trial; abstract-level assessment.
What the sources found
The report describes changes in coagulation and fibrinolysis markers with Vilon. Its abstract does not provide enough allocation, sample-size, effect-size or adverse-event detail for a reliable benefit–risk estimate.
Patients with type 1 diabetes in a Russian report indexed as a randomized controlled trial; abstract-level assessment.
Source · Abstract / selected methods and results / product description
Regulatory scope
Identity documentation and publication do not confer marketing authorization. No new jurisdiction-specific approval claim is made.
What remains unknown
Human report located; full Russian methods/results not obtained in this pass. Indexing as randomized does not establish low risk of bias. No treatment recommendation or clinician sign-off.
How it works
Identity and evidence must be read separately.
Calling Vilon unidentified, or claiming only cell evidence exists, was too broad. Its sequence and a human report are documented, but biomarker findings cannot establish immune enhancement, longevity or a safe general regimen.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- A complete human adverse-effect profile is not established by the selected sources.
Contraindications
- No complete product-specific contraindication assessment is available; absence of a listed risk is not evidence of safety.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Findings
The report describes changes in coagulation and fibrinolysis markers with Vilon. Its abstract does not provide enough allocation, sample-size, effect-size or adverse-event detail for a reliable benefit–risk estimate.
Patients with type 1 diabetes in a Russian report indexed as a randomized controlled trial; abstract-level assessment.
Abstract / selected methods and results / product description
References
Pliss et al. The effect of vilon (Lys-Glu) on dimethylhydrazine-induced neoplasia. 2005. Mouse study.
PMID: 16308980
Kuznik et al. Effect of thymomimetic vilon on coagulation and fibrinolysis in type 1 diabetes. Adv Gerontol. 2006. Russian report.
PMID: 17152731
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.